Sidorenko S V, Rezvan S P, Grudinina S A, Sterkhova G V, Aleksandrova I A
Laboratory of Microbiology, National Research Centre of Antibiotics, Moscow.
Antibiot Khimioter. 1998;43(1):4-14.
Comparative activity of meropenem and other antibacterial drugs against isolates from intensive care and reanimation units of various profiles was estimated. It was shown that the recommendations for the combined therapy with the 3rd generation cephalosporins and aminoglycosides should be revised, since none of the isolates resistant to ceftazidime or cefotaxime was susceptible to gentamicin or tobramycin. At present the most promising agents of empirical therapy are carbapenems (meropenem and imipenem). However, the resistance of methicillin resistant staphylococci and Enterococcus faecium to carbapenems and the intrinsic resistance of some gram-negative bacteria to carbapenems are indicative of the necessity of microbiological diagnosis, especially when the treatment with meropenem fails.
评估了美罗培南和其他抗菌药物对来自不同类型重症监护和复苏病房分离株的比较活性。结果表明,第三代头孢菌素和氨基糖苷类联合治疗的建议应予以修订,因为对头孢他啶或头孢噻肟耐药的分离株对庆大霉素或妥布霉素均不敏感。目前,经验性治疗最有前景的药物是碳青霉烯类(美罗培南和亚胺培南)。然而,耐甲氧西林葡萄球菌和粪肠球菌对碳青霉烯类的耐药性以及一些革兰氏阴性菌对碳青霉烯类的固有耐药性表明有必要进行微生物诊断,尤其是在美罗培南治疗失败时。